Bausch And Lomb Drug Patent Portfolio

Bausch And Lomb owns 9 orange book drugs protected by 31 US patents with Miochol-E having the least patent protection, holding only 1 patent. And Prolensa with maximum patent protection, holding 9 patents. Given below is the list of Bausch And Lomb's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9517220 Bromfenac bioavailability 11 Nov, 2033
Active
US10085958 Bromfenac bioavailability 19 Nov, 2032
Active
US8481526 Fluoroquinolone carboxylic acid molecular crystals 09 Jan, 2031
Active
US8415342 Besifloxacin ophthalmic composition for the treatment or control of infection 07 Nov, 2030
Active
US8604020 Fluoroquinolone carboxylic acid molecular crystals 12 Mar, 2030
Active
US8937062 Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria 13 Nov, 2029
Active
US8058467 Prostaglandin derivatives 21 Feb, 2029
Active
US7273946 Prostaglandin derivatives 03 Oct, 2025
Active
US8129431 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid 11 Sep, 2025
Active
US7629345 Prostaglandin derivatives 05 Jan, 2025
Active
US7910767 Prostaglandin derivatives 05 Jan, 2025
Active
US8669290 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid 16 Jan, 2024 Expired
US8754131 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid 16 Jan, 2024 Expired
US8871813 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid 16 Jan, 2024 Expired
US8927606 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid 16 Jan, 2024 Expired
US9144609 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid 16 Jan, 2024 Expired
US9561277 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid 16 Jan, 2024 Expired
US6685958 Quinolone carboxylic acid compositions and related methods of treatment 29 Jun, 2021 Expired
US6261546 Methods and compositions for stabilizing acetylcholine compositions 29 Apr, 2019 Expired
US6699492 Quinolone carboxylic acid compositions and related methods of treatment 31 Mar, 2019 Expired
US6217895 Method for treating and/or preventing retinal diseases with sustained release corticosteroids 22 Mar, 2019 Expired
US6548078 Method for treating and/or preventing retinal diseases with sustained release corticosteroids 22 Mar, 2019 Expired
US6645963 Prolonged-action eye drop 16 Nov, 2018 Expired
US6335335 Prolonged-action eye drop 02 Nov, 2018 Expired
US6211233 Prostaglandin pharmaceutical compositions 17 Jun, 2018 Expired
US5447926 Quinolone carboxylic acid derivatives 13 Apr, 2016 Expired
US5540930 Suspension of loteprednol etabonate for ear, eye, or nose treatment 25 Apr, 2014 Expired
US5747061 Suspension of loteprednol etabonate for ear, eye, or nose treatment 25 Apr, 2014 Expired
US5540930 Suspension of loteprednol etabonate for ear, eye, or nose treatment 25 Oct, 2013 Expired
US5747061 Suspension of loteprednol etabonate for ear, eye, or nose treatment 25 Oct, 2013 Expired
US4996335 Soft steroids having anti-inflammatory activity 09 Sep, 2012 Expired


Given below is the list of recent legal activities going on the following drug patents of Bausch And Lomb.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 22 May, 2024 US9517220
Patent Term Extension Certificate 18 Mar, 2024 US8058467
Withdrawal of Application for PTE 18 Mar, 2024 US7629345
Withdrawal of Application for PTE 18 Mar, 2024 US7273946
Notice of Final Determination -Election Required 13 Feb, 2024 US8058467
Notice of Final Determination -Election Required 13 Feb, 2024 US7273946
Notice of Final Determination -Election Required 13 Feb, 2024 US7629345
Resp. to req. for info. sent under 37 CFR 1.750 02 Feb, 2024 US7629345
Resp. to req. for info. sent under 37 CFR 1.750 02 Feb, 2024 US8058467
Resp. to req. for info. sent under 37 CFR 1.750 02 Feb, 2024 US7273946
Requirement for information sent under 37 CFR 1.750 26 Jan, 2024 US7629345
Requirement for information sent under 37 CFR 1.750 26 Jan, 2024 US7273946
Requirement for information sent under 37 CFR 1.750 26 Jan, 2024 US8058467
FDA Final Eligibility Letter 14 Nov, 2023 US7629345
transaction for FDA Determination of Regulatory Review Period 04 May, 2023 US7273946


Bausch And Lomb's Drug Patent Litigations

Bausch And Lomb's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 26, 2014, against patent number US8669290. The petitioner Metrics, Inc., challenged the validity of this patent, with SENJU PHARMACEUTICAL CO., LTD. as the respondent. Click below to track the latest information on how companies are challenging Bausch And Lomb's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8669290 April, 2015 FWD Entered
(12 Sep, 2016)
SENJU PHARMACEUTICAL CO., LTD. Lupin Ltd.
US8754131 April, 2015 FWD Entered
(12 Sep, 2016)
SENJU PHARMACEUTICAL CO., LTD. Lupin Ltd.
US8754131 November, 2015 FWD Entered
(12 Sep, 2016)
SENJU PHARMACEUTICAL CO., LTD. InnoPharma Licensing, Inc.
US8871813 April, 2015 FWD Entered
(12 Sep, 2016)
SENJU PHARMACEUTICAL CO., LTD. Lupin Ltd.
US8871813 November, 2015 FWD Entered
(12 Sep, 2016)
SENJU PHARMACEUTICAL CO., LTD. InnoPharma Licensing, Inc.
US8927606 April, 2015 FWD Entered
(12 Sep, 2016)
Senju Pharmaceutical Co., Ltd. Lupin Ltd.
US8927606 November, 2015 FWD Entered
(12 Sep, 2016)
SENJU PHARMACEUTICAL CO., LTD. InnoPharma Licensing, Inc.
US8129431 September, 2015 FWD Entered
(05 Aug, 2016)
SENJU PHARMACEUTICAL CO., LTD. Lupin Ltd.
US8129431 March, 2015 FWD Entered
(28 Jul, 2016)
Senju Pharmaceutical Co., Ltd. InnoPharma, Licensing, Inc.
US8669290 March, 2015 FWD Entered
(28 Jul, 2016)
SENJU PHARMACEUTICAL CO., LTD. InnoPharma Licensing, Inc.
US8129431 June, 2014 Terminated-Settled
(08 Jul, 2015)
Senju Pharmaceutical Co., Ltd. Metrics, Inc. c/o Duane Morris LLP
US8669290 June, 2014 Terminated-Settled
(08 Jul, 2015)
SENJU PHARMACEUTICAL CO., LTD. Metrics, Inc.


Bausch And Lomb Drug Patents' Oppositions Filed in EPO

Bausch And Lomb drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 30, 2009, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP04702854A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP04804405A Nov, 2016 Teva Pharmaceutical Industries Ltd Opposition rejected
EP04702854A Jan, 2009 Teva Pharmaceutical Industries Ltd. Opposition procedure closed


Bausch And Lomb's Family Patents

Bausch And Lomb drugs have patent protection in a total of 43 countries. It's US patent count contributes only to 25.0% of its total global patent coverage. 9 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Bausch And Lomb Drug List

Given below is the complete list of Bausch And Lomb's drugs and the patents protecting them.


1. Alrex

Alrex is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5540930
(Pediatric)
Suspension of loteprednol etabonate for ear, eye, or nose treatment 25 Apr, 2014
(10 years ago)
Expired
US5747061
(Pediatric)
Suspension of loteprednol etabonate for ear, eye, or nose treatment 25 Apr, 2014
(10 years ago)
Expired
US5540930 Suspension of loteprednol etabonate for ear, eye, or nose treatment 25 Oct, 2013
(10 years ago)
Expired
US5747061 Suspension of loteprednol etabonate for ear, eye, or nose treatment 25 Oct, 2013
(10 years ago)
Expired
US4996335
(Pediatric)
Soft steroids having anti-inflammatory activity 09 Sep, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Alrex's drug page


2. Besivance

Besivance is protected by 7 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8481526 Fluoroquinolone carboxylic acid molecular crystals 09 Jan, 2031
(6 years from now)
Active
US8415342 Besifloxacin ophthalmic composition for the treatment or control of infection 07 Nov, 2030
(6 years from now)
Active
US8604020 Fluoroquinolone carboxylic acid molecular crystals 12 Mar, 2030
(5 years from now)
Active
US8937062 Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria 13 Nov, 2029
(5 years from now)
Active
US6685958 Quinolone carboxylic acid compositions and related methods of treatment 29 Jun, 2021
(3 years ago)
Expired
US6699492 Quinolone carboxylic acid compositions and related methods of treatment 31 Mar, 2019
(5 years ago)
Expired
US5447926 Quinolone carboxylic acid derivatives 13 Apr, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Besivance's drug page


3. Istalol

Istalol is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6645963 Prolonged-action eye drop 16 Nov, 2018
(5 years ago)
Expired
US6335335 Prolonged-action eye drop 02 Nov, 2018
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Istalol's drug page


4. Lotemax

Lotemax is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5540930
(Pediatric)
Suspension of loteprednol etabonate for ear, eye, or nose treatment 25 Apr, 2014
(10 years ago)
Expired
US5747061
(Pediatric)
Suspension of loteprednol etabonate for ear, eye, or nose treatment 25 Apr, 2014
(10 years ago)
Expired
US5540930 Suspension of loteprednol etabonate for ear, eye, or nose treatment 25 Oct, 2013
(10 years ago)
Expired
US5747061 Suspension of loteprednol etabonate for ear, eye, or nose treatment 25 Oct, 2013
(10 years ago)
Expired
US4996335
(Pediatric)
Soft steroids having anti-inflammatory activity 09 Sep, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lotemax's drug page


5. Miochol-e

Miochol-e is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6261546 Methods and compositions for stabilizing acetylcholine compositions 29 Apr, 2019
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Miochol-e's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Prolensa

Prolensa is protected by 9 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9517220 Bromfenac bioavailability 11 Nov, 2033
(9 years from now)
Active
US10085958 Bromfenac bioavailability 19 Nov, 2032
(8 years from now)
Active
US8129431 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid 11 Sep, 2025
(11 months from now)
Active
US8669290 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid 16 Jan, 2024
(8 months ago)
Expired
US8754131 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid 16 Jan, 2024
(8 months ago)
Expired
US8871813 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid 16 Jan, 2024
(8 months ago)
Expired
US8927606 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid 16 Jan, 2024
(8 months ago)
Expired
US9144609 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid 16 Jan, 2024
(8 months ago)
Expired
US9561277 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid 16 Jan, 2024
(8 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prolensa's drug page


7. Retisert

Retisert is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6217895 Method for treating and/or preventing retinal diseases with sustained release corticosteroids 22 Mar, 2019
(5 years ago)
Expired
US6548078 Method for treating and/or preventing retinal diseases with sustained release corticosteroids 22 Mar, 2019
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Retisert's drug page


8. Vyzulta

Vyzulta is protected by 5 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8058467 Prostaglandin derivatives 21 Feb, 2029
(4 years from now)
Active
US7273946 Prostaglandin derivatives 03 Oct, 2025
(11 months from now)
Active
US7629345 Prostaglandin derivatives 05 Jan, 2025
(2 months from now)
Active
US7910767 Prostaglandin derivatives 05 Jan, 2025
(2 months from now)
Active
US6211233 Prostaglandin pharmaceutical compositions 17 Jun, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vyzulta's drug page


9. Zylet

Zylet is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5540930
(Pediatric)
Suspension of loteprednol etabonate for ear, eye, or nose treatment 25 Apr, 2014
(10 years ago)
Expired
US5747061
(Pediatric)
Suspension of loteprednol etabonate for ear, eye, or nose treatment 25 Apr, 2014
(10 years ago)
Expired
US5540930 Suspension of loteprednol etabonate for ear, eye, or nose treatment 25 Oct, 2013
(10 years ago)
Expired
US5747061 Suspension of loteprednol etabonate for ear, eye, or nose treatment 25 Oct, 2013
(10 years ago)
Expired
US4996335
(Pediatric)
Soft steroids having anti-inflammatory activity 09 Sep, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zylet's drug page